Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 15/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 10/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13664270 | 0.86 | GAA (0.48) | CNR1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL13664272 | 0.83 | GAA (0.47) | CNR1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL13664200 | 0.82 | MAPT (0.42) | CNR1MAPTKDM4EMEN1MAPK1 | |
| SCHEMBL13664481 | 0.82 | L3MBTL1 (0.43) | CNR1CNR2POLBGAATDP1 | |
| SCHEMBL13664271 | 0.80 | GAA (0.49) | CNR1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL13664274 | 0.79 | GAA (0.48) | MAPTKDM4EMEN1KMT2APOLB | |
| SCHEMBL13664525 | 0.77 | MAPT (0.42) | CNR1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL13664277 | 0.77 | MAPT (0.43) | CNR1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL13664506 | 0.77 | MAPT (0.46) | CNR1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL13664491 | 0.77 | GAA (0.46) | CNR1MAPTKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253673-A1 | Substituted Pyrazoles as Ghrelin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
| US-20090253673-A1 | Substituted Pyrazoles as Ghrelin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253673-A1 | Substituted Pyrazoles as Ghrelin Receptor Antagonists | GIPR, GPR119, GLP1R | CNR1 367/4885MAPT 4701/4885KDM4E 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.